The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.

已完结 10 由 jxxjxx 发布于 2025/7/4 16:49:52

DOI:10.1080/10428194.2017.1312387
作者：Andrew Aw, Jennifer R Brown
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1080/10428194.2017.1312387

Taylor & Francis

Abstract：The recent development of small molecule inhibitors targeted at the B-cell receptor (BCR) pathway and the anti-apoptotic protein BCL-2 has revolutionized the care of patients with chronic ly

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerPhase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.